DendroPharm GmbH

DendroPharm was founded by Sam Dylan Moré, Henrik Luessen, Margret Moré, Emanuel Fleige, and Florian Paulus as a spin-off from the Freie Universität Berlin in 2013. We are dedicated to the development of novel excipients and innovative therapies for severe and chronic diseases. DendroPharm GmbH offers contract manufacturing for clinical trial samples for semi-solids. We also offer stability studies with GMP-conform analytics. We are out-licensing a novel nanotech platform technology which significantly reduces sedation, addiction, constipation in patients using strong opiod medication. We are further outlicensing a platform technology for cancer therapy - due to the accumulation of small molecular drugs side effects of chemotherapy can be significantly reduced